Display options
Cite
Cornmark L, Holmgren C, Masoumi K, et al. PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics. Cell Death Discov. 2016;2:16002doi: 10.1038/cddiscovery.2016.2.
Cornmark, L., Holmgren, C., Masoumi, K., & Larsson, C. (2016). PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics. Cell death discovery, 216002. https://doi.org/10.1038/cddiscovery.2016.2
Cornmark, L, et al. "PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics." Cell death discovery vol. 2 (2016): 16002. doi: https://doi.org/10.1038/cddiscovery.2016.2
Cornmark L, Holmgren C, Masoumi K, Larsson C. PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics. Cell Death Discov. 2016 Feb 29;2:16002. doi: 10.1038/cddiscovery.2016.2. eCollection 2016. PMID: 27551497; PMCID: PMC4979953.
Copy Download .nbib Format: NLM
Share it on

Cell Death Discov. 2016 Feb 29;2:16002. doi: 10.1038/cddiscovery.2016.2. eCollection 2016.

PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics.

Cell death discovery

L Cornmark, C Holmgren, K Masoumi, C Larsson

Affiliations

  1. Department of Laboratory Medicine, Translational Cancer Research, Lund University , Lund, Sweden.

PMID: 27551497 PMCID: PMC4979953 DOI: 10.1038/cddiscovery.2016.2

Abstract

There is a need for novel strategies to initiate cancer cell death. One approach is the use of Smac mimetics, which antagonize inhibitor of apoptosis proteins (IAPs). Recent studies have shown that combinations of Smac mimetics such as LBW242 or LCL161 in combination with chemotherapeutic agents increase cancer cell death. Here we show that the protein kinase C (PKC) activator TPA together with the Smac mimetic LBW242 induces cell death in two basal breast cancer cell lines (MDA-MB-468 and BT-549) that are resistant to Smac mimetic as single agent. Ten other LBW242-insensitive cancer cell lines were not influenced by the TPA+LBW242 combination. The TPA+LBW242 effect was suppressed by the PKC inhibitor GF109203X, indicating dependence on PKC enzymatic activity. The PKC effect was mediated via increased synthesis and release of TNFα, which can induce death in the presence of Smac mimetics. The cell death, coinciding with caspase-3 cleavage, was suppressed by caspase inhibition and preceded by the association of RIP1 with caspase-8, as seen in complex II formation. Smac mimetics, but not TPA, induced the non-canonical NF-κB pathway in both MDA-MB-231 and MDA-MB-468 cells. Blocking the canonical NF-κB pathway suppressed TPA induction of TNFα in MDA-MB-468 cells whereas isolated downregulation of either the canonical or non-canonical pathways did not abolish the Smac mimetic induction of the NF-κB driven genes TNFα and BIRC3 in MDA-MB-231 cells although the absolute levels were suppressed. A combined downregulation of the canonical and non-canonical pathways further suppressed TNFα levels and inhibited Smac mimetic-mediated cell death. Our data suggest that in certain basal breast cancer cell lines co-treatment of TPA with a Smac mimetic induces cell death highlighting the potential of using these pathways as molecular targets for basal-like breast cancers.

References

  1. Cell Death Dis. 2013 Mar 28;4:e564 - PubMed
  2. Oncogene. 2014 Nov 27;33(48):5534-45 - PubMed
  3. Cell Death Dis. 2013 Jul 18;4:e733 - PubMed
  4. Cancer Cell. 2007 Nov;12(5):445-56 - PubMed
  5. Nat Immunol. 2008 Dec;9(12):1371-8 - PubMed
  6. Cell. 1986 Dec 26;47(6):921-8 - PubMed
  7. J Biol Chem. 2011 Jul 29;286(30):26406-17 - PubMed
  8. Cell. 2007 Nov 16;131(4):682-93 - PubMed
  9. Nat Immunol. 2008 Dec;9(12):1364-70 - PubMed
  10. Cell Death Dis. 2014 Dec 11;5:e1562 - PubMed
  11. Nature. 2006 May 25;441(7092):431-6 - PubMed
  12. Breast Cancer Res Treat. 2007 Apr;102(2):157-72 - PubMed
  13. Mol Cell. 2011 Aug 5;43(3):432-48 - PubMed
  14. Cell Signal. 2008 Jul;20(7):1338-48 - PubMed
  15. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  16. Mod Pathol. 2002 Feb;15(2):159-66 - PubMed
  17. Nat Biotechnol. 2014 Feb;32(2):182-90 - PubMed
  18. Breast Cancer Res Treat. 2013 Jan;137(2):359-71 - PubMed
  19. Oncogene. 1999 Nov 22;18(49):6853-66 - PubMed
  20. FEBS Lett. 2012 Apr 24;586(8):1166-72 - PubMed
  21. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  22. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11778-83 - PubMed
  23. Cancer Res. 2011 Dec 15;71(24):7640-8 - PubMed
  24. J Biol Chem. 2004 Sep 17;279(38):39223-31 - PubMed
  25. Mol Cell. 2007 Dec 14;28(5):914-22 - PubMed
  26. J Biol Chem. 2012 Oct 26;287(44):37570-82 - PubMed
  27. Nat Rev Mol Cell Biol. 2010 Sep;11(9):621-32 - PubMed
  28. Nat Rev Mol Cell Biol. 2008 Aug;9(8):655-62 - PubMed
  29. Oncogene. 2005 Oct 20;24(46):6945-56 - PubMed
  30. Cell. 2003 Jul 25;114(2):181-90 - PubMed
  31. Nat Cell Biol. 2014 Aug;16(8):728-36 - PubMed
  32. Cell. 1988 Apr 22;53(2):211-7 - PubMed
  33. Cancer Res. 2012 Mar 1;72 (5):1229-38 - PubMed
  34. Oncol Res. 1994;6(4-5):203-10 - PubMed
  35. Nat Rev Drug Discov. 2012 Feb 01;11(2):109-24 - PubMed
  36. Cell Death Differ. 2015 Sep;22(9):1463-76 - PubMed
  37. EMBO J. 2012 Jan 4;31(1):14-28 - PubMed
  38. Cell Death Differ. 2012 Jan;19(1):107-20 - PubMed
  39. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 - PubMed
  40. Oncogene. 2013 Feb 21;32(8):988-97 - PubMed
  41. Cell. 2007 Nov 16;131(4):669-81 - PubMed
  42. Oncogene. 2006 Aug 7;25(34):4798-811 - PubMed
  43. Cancer Res. 2012 May 15;72(10):2645-56 - PubMed
  44. Cell. 2009 Jul 23;138(2):229-32 - PubMed

Publication Types